ITOS
Price
$6.67
Change
-$0.04 (-0.60%)
Updated
May 9 closing price
Capitalization
255.09M
89 days until earnings call
NVAX
Price
$5.97
Change
-$0.69 (-10.36%)
Updated
May 9 closing price
Capitalization
967.77M
88 days until earnings call
Ad is loading...

ITOS vs NVAX

Header iconITOS vs NVAX Comparison
Open Charts ITOS vs NVAXBanner chart's image
iTeos Therapeutics
Price$6.67
Change-$0.04 (-0.60%)
Volume$253.47K
Capitalization255.09M
Novavax
Price$5.97
Change-$0.69 (-10.36%)
Volume$20.02M
Capitalization967.77M
ITOS vs NVAX Comparison Chart
Loading...
ITOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ITOS vs. NVAX commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ITOS is a Hold and NVAX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (ITOS: $6.66 vs. NVAX: $5.97)
Brand notoriety: ITOS: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ITOS: 56% vs. NVAX: 306%
Market capitalization -- ITOS: $255.09M vs. NVAX: $967.77M
ITOS [@Biotechnology] is valued at $255.09M. NVAX’s [@Biotechnology] market capitalization is $967.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ITOS’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • ITOS’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ITOS is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ITOS’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • ITOS’s TA Score: 5 bullish, 5 bearish.
  • NVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ITOS is a better buy in the short-term than NVAX.

Price Growth

ITOS (@Biotechnology) experienced а -14.22% price change this week, while NVAX (@Biotechnology) price change was -6.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

ITOS is expected to report earnings on Aug 07, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($968M) has a higher market cap than ITOS($255M). ITOS YTD gains are higher at: -13.216 vs. NVAX (-25.684). NVAX has higher annual earnings (EBITDA): -108.04M vs. ITOS (-153.09M). NVAX has more cash in the bank: 923M vs. ITOS (495M). ITOS has less debt than NVAX: ITOS (5.1M) vs NVAX (230M). NVAX has higher revenues than ITOS: NVAX (682M) vs ITOS (35M).
ITOSNVAXITOS / NVAX
Capitalization255M968M26%
EBITDA-153.09M-108.04M142%
Gain YTD-13.216-25.68451%
P/E RatioN/AN/A-
Revenue35M682M5%
Total Cash495M923M54%
Total Debt5.1M230M2%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ITOSNVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 9 days ago
72%
Bullish Trend 19 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
ITOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

ITOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ITOS has been loosely correlated with BMRN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ITOS jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ITOS
1D Price
Change %
ITOS100%
-0.52%
BMRN - ITOS
45%
Loosely correlated
-1.60%
RCUS - ITOS
43%
Loosely correlated
-2.93%
IBO - ITOS
41%
Loosely correlated
+10.45%
IMNM - ITOS
41%
Loosely correlated
-3.24%
NVAX - ITOS
39%
Loosely correlated
-10.29%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with ITOS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-10.29%
ITOS - NVAX
39%
Loosely correlated
-0.52%
ARCT - NVAX
35%
Loosely correlated
-3.51%
BNTX - NVAX
35%
Loosely correlated
-2.12%
MRNA - NVAX
34%
Loosely correlated
-0.53%
PPTDF - NVAX
32%
Poorly correlated
N/A
More